Welcome to our dedicated page for FTRPF news (Ticker: FTRPF), a resource for investors and traders seeking the latest updates and insights on FTRPF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect FTRPF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of FTRPF's position in the market.
Field Trip Health Ltd. has received final approval to list its common shares on the NASDAQ Global Select Market, starting July 29, 2021, under the ticker FTRP. This milestone reflects the company's rapid progress in the psychedelics industry. President Hannan Fleiman highlighted the achievement as a testament to their team's efforts, while Chief Clinical Officer Dr. Ryan Yermus emphasized increased investor access and ongoing development of their psychedelic molecule, FT-104. Concurrently, there will be changes in the company's compensation committee and board of directors.
Field Trip Health Ltd. (TSX: FTRP; OTCQX: FTRPF) has received conditional approval to list its common shares on the NASDAQ Global Select Market. The final approval depends on fulfilling NASDAQ's remaining conditions. The company anticipates this listing will enhance liquidity and attract more investors, ultimately increasing shareholder value. Field Trip is a leader in psychedelic therapies, focusing on drug development and expanding its health clinics. The company has completed necessary steps to ensure eligibility for electronic clearing through the Depository Trust Company.
Field Trip Health Ltd. announces participation in the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit on July 13, 2021. Ronan Levy, Co-Founder & Executive Chairman, will engage in a panel discussion titled “Emerging Psychedelic Therapies In The Field Of Neuropsych” at 4:15 PM EST. The company is a leader in developing psychedelic therapies, with a significant focus on innovative treatments and research.
For investor meetings, please reach out to Cowen representatives for scheduling.
Field Trip Health closed FY2021 as a leading vertically integrated psychedelics company with $111.8 million in cash post two successful offerings totaling $115 million. Its drug development advances with FT-104, currently in GMP production for Phase 1 studies. Patient services revenue surged 66% in Q4, reaching $526,435. Six new Field Trip Health centers are operational, with plans for more expansions in Canada and the U.S. Despite a net loss of $23.1 million, Field Trip aims to capitalize on the anticipated $100 billion psychedelics market, enhancing its therapeutic offerings and clinic network.
Field Trip Health Ltd. (TSX: FTRP; OTCQX: FTRPF) will release its fiscal fourth-quarter and full-year 2021 financial results after market close on June 24, 2021. A conference call to discuss the results is scheduled for June 25 at 8:00 am ET. The webcast can be accessed via their Investor Relations website. Field Trip is focused on developing psychedelic therapies and operates clinics across North America and Europe, aiming to provide evidence-based healing solutions.
Field Trip Health Ltd. (OTCQX: FTRPF) announced the completion of initial drug metabolism and pharmacokinetic (DMPK) studies for its psychedelic compound FT-104, paving the way for a Phase 1 human trials application by year-end. The studies confirmed FT-104's rapid and complete metabolism, with a fast elimination profile, ensuring a reliably short psychedelic experience. Additionally, the company secured a Good Manufacturing Practices compliant partner for FT-104 manufacturing. Field Trip aims to finalize its safety and pharmacology package for submission to regulators for trial approvals.
Field Trip Health Ltd. (OTCQX: FTRPF) announced its application to list common shares on the NASDAQ, aiming to enhance visibility among global investors. Executive Chairman Ronan Levy emphasized the potential of psychedelics to disrupt psychiatry, while President Hannan Fleiman noted the advancement of drug candidate FT-104. By the end of 2021, the company expects to begin Phase 1 human trials for FT-104 and operate 20 health centers across North America. The NASDAQ listing is pending regulatory approval, but shares will remain on the Toronto Stock Exchange and quoted on OTCQX during the process.
Field Trip Health Ltd. (CSE: FTRP; OTCQX: FTRPF) will begin trading on the Toronto Stock Exchange (TSX) from June 7, 2021. This transition from the Canadian Securities Exchange (CSE) includes the delisting of common shares and warrants from the CSE, with no changes to the share structure.
Additionally, Barry Fishman and Ellen Lubman have joined the Board of Directors, enhancing leadership with their extensive industry experience. The company aims to position itself as a leader in psychedelic therapies and mental health sectors.
Field Trip Health Ltd. has received conditional approval to list its common shares and warrants on the Toronto Stock Exchange (TSX). This move is aimed at enhancing visibility and liquidity for investors. The company is working to meet the TSX's requirements, and once approved, shares will be delisted from the Canadian Securities Exchange (CSE) and commence trading on the TSX under the symbol 'FTRP'. The current OTCQX trading symbol will remain 'FTRPF'. CEO Joseph del Moral emphasized the significance of this milestone for both the company and the psychedelics industry.
